进入创新通道！经导管植入式无导线心脏起搏器

Company Overview - Dunbo Medical, established in 2018, is headquartered in Xi'an, Shaanxi Province, focusing on the research and production of Class III active implantable medical devices [27] - The company has developed key medical and semiconductor technologies, including proprietary mixed-signal chips, hardware circuits, software applications, and structural materials [27] - Dunbo Medical has completed four rounds of financing to support its growth and innovation [27] Product Introduction - Dunbo's core product is a leadless cardiac pacemaker, which integrates the pulse generator and pacing electrode into a compact capsule that can be directly implanted into the heart [14][15] - The leadless pacemaker has advantages such as a smaller size (0.8cc), ease of use, and safety, eliminating complications associated with traditional lead-based systems [10][15] - The product's design allows for no visible skin incision or scarring, reducing the risk of infection and damage associated with lead wires [14][15] Market Overview - The prevalence of heart failure in China is increasing, with approximately 13.7 million patients aged 35 and older, and an annual increase of around 3 million new cases [16] - The cardiac pacemaker market in China is projected to reach 6.8 billion yuan in 2024, with imported products holding a market share of 89%, indicating a significant opportunity for domestic alternatives [16] - Despite the absence of successful domestic CRT products, there have been notable advancements in other innovative devices for heart failure treatment, such as left ventricular assist devices and cardiac contractility modulators [16][27] Innovations in Heart Failure Treatment - The left ventricular assist device (LVAD) market is maturing, with four domestic systems approved for market, each with unique advantages [17][18][20][22] - The D-shunt atrial shunt device has entered the "national innovative medical device" green channel, with plans for market approval in early 2024 [23][24] - The cardiac contractility modulator (CCM) developed by Lepu Medical has passed special review and is expected to receive approval soon [25]